[1] ZHANG Y, SUN X, ICLI B, et al. Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy[J]. Endocrine reviews, 2017, 38(2): 145-168.
[2] COLE J, FLOREZ J. Genetics of diabetes mellitus and diabetes complications[J]. Nature reviews. Nephrology, 2020, 16(7): 377-390.
[3] SOLOMON S, CHEW E, DUH E, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association[J]. Diabetes care, 2017, 40(3): 412-418.
[4] VUJOSEVIC S, ALDINGTON S, SILVA P, et al. Screening for diabetic retinopathy: new perspectives and challenges[J]. The lancet. Diabetes & endocrinology, 2020, 8(4): 337-347.
[5] SABANAYAGAM C, BANU R, CHEE M, et al. Incidence and progression of diabetic retinopathy: a systematic review[J]. The lancet. Diabetes & endocrinology, 2019, 7(2): 140-149.
[6] FONG D, AIELLO L, GARDNER T, et al. Retinopathy in diabetes[J]. Diabetes care, 2004, : S84-87.
[7] BRENNAN E, MOHAN M, ANDREWS D, et al. Specialized pro-resolving mediators in diabetes: novel therapeutic strategies[J]. Clinical science (London, England : 1979), 2019, 133(21): 2121-2141.
[8] PITSAVOS C, TAMPOURLOU M, PANAGIOTAKOS D, et al. Association Between Low-Grade Systemic Inflammation and Type 2 Diabetes Mellitus Among Men and Women from the ATTICA Study[J]. The review of diabetic studies : RDS, 2007, 4(2): 98-104.
[9] R BSAM A, PARIKH S, FORT P. Role of Inflammation in Diabetic Retinopathy[J]. International journal of molecular sciences, 2018, 19(4).
[10] DEHDASHTIAN E, MEHRZADI S, YOUSEFI B, et al. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress[J]. Life sciences, 2018, 193: 20-33.
[11] SPENCER B, ESTEVEZ J, LIU E, et al. Pericytes, inflammation, and diabetic retinopathy[J]. Inflammopharmacology, 2020, 28(3): 697-709.
[12] CORBEAU I, THEZENAS S, MARAN-GONZALEZ A, et al. Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy[J]. Cancers, 2020, 12(9).
[13] BILEN M, MARTINI D, LIU Y, et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy[J]. Cancer, 2019, 125(1): 127-134.
[14] AVCIL S. Evaluation of the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as inflammatory markers in children with attention-deficit hyperactivity disorder[J]. Psychiatry and clinical neurosciences, 2018, 72(7): 522-530.
[15] KIM H, CHOI H, LEE M, et al. Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study[J]. Cancer research and treatment, 2016, 48(1): 250-258.
[16] CHOI Y, LEE J, LEE S, et al. A High Monocyte-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Advanced Gallbladder Cancer Receiving Chemotherapy[J]. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019, 28(6): 1045-1051.
[17] HUANG Y, DENG W, ZHENG S, et al. Relationship between monocytes to lymphocytes ratio and axial spondyloarthritis[J]. International immunopharmacology, 2018, 57: 43-46.
[18] JIN Y, XIE M, YANG C, et al. Prognostic value of peripheral blood markers in patients with myositis-associated interstitial lung diseases[J]. Scandinavian journal of rheumatology, 2021, : 1-9.
[19] LIU J, LIU X, LI Y, et al. The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: a meta-analysis[J]. Bioscience reports, 2018, 38(3).
[20] LUO W, ZHANG W. The relationship of blood cell-associated inflammatory indices and diabetic retinopathy: a Meta-analysis and systematic review[J]. International journal of ophthalmology, 2019, 12(2): 312-323.
[21] VERDOIA M, SCHAFFER A, BARBIERI L, et al. Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease[J]. Diabetes & metabolism, 2015, 41(4): 304-311.
[22] PUAVILAI G, CHANPRASERTYOTIN S, SRIPHRAPRADAENG A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization[J]. Diabetes Res Clin Pract, 1999, 44(1): 21-26.
[23] WILKINSON C, FERRIS F, KLEIN R, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682.
[24] DEFRONZO R, FERRANNINI E, GROOP L, et al. Type 2 diabetes mellitus[J]. Nature reviews. Disease primers, 2015, 1: 15019.
[25] OCKRIM Z, YORSTON D. Managing diabetic retinopathy[J]. BMJ (Clinical research ed.), 2010, 341: c5400.
[26] SCHORR S, HAMMES H, M LLER U, et al. The Prevention and Treatment of Retinal Complications in Diabetes[J]. Deutsches Arzteblatt international, 2016, 113(48): 816-823.
[27] AHLQVIST E, VAN ZUYDAM N, GROOP L, et al. The genetics of diabetic complications[J]. Nature reviews. Nephrology, 2015, 11(5): 277-287.
[28] WONG T Y, CHEUNG C M G, LARSEN M, et al. diabetic retinopathy[J]. Nature Reviews Disease Primers, 2016, 2: 16030.
[29] ULU S, DOGAN M, AHSEN A, et al. Neutrophil-to-lymphocyte ratio as a quick and reliable predictive marker to diagnose the severity of diabetic retinopathy[J]. Diabetes technology & therapeutics, 2013, 15(11): 942-947.
[30] YUE S, ZHANG J, WU J, et al. Use of the Monocyte-to-Lymphocyte Ratio to Predict Diabetic Retinopathy[J]. International journal of environmental research and public health, 2015, 12(8): 10009-10019.
[31] WANG J, CHEN Z, YANG K, et al. Association between neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and diabetic retinopathy among diabetic patients without a related family history[J]. Diabetology & metabolic syndrome, 2020, 12: 55.